Amid R&D rejigs, GlaxoSmithKline axes 6 pipeline assets

Submitted by admin on February 6, 2019 - 9:50am

Source:

Fierce Biotech

News Tags:

Headline:

snippet:

GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clear-out.

Search form